Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

Kealy R. Ham, David W. Boldt, Michael T. McCurdy, Laurence W. Busse, Raphael Favory, Michelle Ng Gong, Ashish K. Khanna, Stefan N. Chock, Feng Zeng, Lakhmir S. Chawla, George F. Tidmarsh, Marlies Ostermann

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg−1 min−1 angiotensin II at 30 min (≤ 5 ng kg−1 min−1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus patients receiving > 5 ng kg−1 min−1 angiotensin II at 30 min (> 5 ng kg−1 min−1 subgroup). Data from angiotensin II-treated patients enrolled in the ATHOS-3 trial were used. Results: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg−1 min−1 at treatment initiation to ≤ 5 ng kg−1 min−1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg−1 min−1 subgroup (84/163). Patients in the ≤ 5 ng kg−1 min−1 subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg−1 min−1 subgroup (90% vs. 51%, respectively; odds ratio, 8.46 [95% CI 3.63–19.7], P < 0.001). Day 28 survival was also higher in the ≤ 5 ng kg−1 min−1 subgroup versus the > 5 ng kg−1 min−1 subgroup (59% vs. 33%, respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], P = 0.0007); multivariate analyses supported the survival benefit in patients with lower angiotensin II levels. The ≤ 5 ng kg−1 min−1 subgroup had a more favorable safety profile and lower treatment discontinuation rate than the > 5 ng kg−1 min−1 subgroup. Conclusions: This prespecified analysis showed that down-titration to ≤ 5 ng kg−1 min−1 angiotensin II at 30 min is an early predictor of favorable clinical outcomes which may be related to relative angiotensin II insufficiency.

Original languageEnglish (US)
Article number63
JournalAnnals of Intensive Care
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Angiotensin II
Shock
Arterial Pressure
Norepinephrine
Multivariate Analysis
Odds Ratio
Safety
Survival
Therapeutics
Serum

Keywords

  • Angiotensin II
  • Dose response
  • Hypotension
  • Septic shock
  • Shock

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Sensitivity to angiotensin II dose in patients with vasodilatory shock : a prespecified analysis of the ATHOS-3 trial. / Ham, Kealy R.; Boldt, David W.; McCurdy, Michael T.; Busse, Laurence W.; Favory, Raphael; Gong, Michelle Ng; Khanna, Ashish K.; Chock, Stefan N.; Zeng, Feng; Chawla, Lakhmir S.; Tidmarsh, George F.; Ostermann, Marlies.

In: Annals of Intensive Care, Vol. 9, No. 1, 63, 01.12.2019.

Research output: Contribution to journalArticle

Ham, KR, Boldt, DW, McCurdy, MT, Busse, LW, Favory, R, Gong, MN, Khanna, AK, Chock, SN, Zeng, F, Chawla, LS, Tidmarsh, GF & Ostermann, M 2019, 'Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial', Annals of Intensive Care, vol. 9, no. 1, 63. https://doi.org/10.1186/s13613-019-0536-5
Ham, Kealy R. ; Boldt, David W. ; McCurdy, Michael T. ; Busse, Laurence W. ; Favory, Raphael ; Gong, Michelle Ng ; Khanna, Ashish K. ; Chock, Stefan N. ; Zeng, Feng ; Chawla, Lakhmir S. ; Tidmarsh, George F. ; Ostermann, Marlies. / Sensitivity to angiotensin II dose in patients with vasodilatory shock : a prespecified analysis of the ATHOS-3 trial. In: Annals of Intensive Care. 2019 ; Vol. 9, No. 1.
@article{6b3733747fda447995f7ba8b6325d6fc,
title = "Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial",
abstract = "Background: Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg−1 min−1 angiotensin II at 30 min (≤ 5 ng kg−1 min−1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus patients receiving > 5 ng kg−1 min−1 angiotensin II at 30 min (> 5 ng kg−1 min−1 subgroup). Data from angiotensin II-treated patients enrolled in the ATHOS-3 trial were used. Results: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg−1 min−1 at treatment initiation to ≤ 5 ng kg−1 min−1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg−1 min−1 subgroup (84/163). Patients in the ≤ 5 ng kg−1 min−1 subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg−1 min−1 subgroup (90{\%} vs. 51{\%}, respectively; odds ratio, 8.46 [95{\%} CI 3.63–19.7], P < 0.001). Day 28 survival was also higher in the ≤ 5 ng kg−1 min−1 subgroup versus the > 5 ng kg−1 min−1 subgroup (59{\%} vs. 33{\%}, respectively; hazard ratio, 0.48 [95{\%} CI 0.28–0.72], P = 0.0007); multivariate analyses supported the survival benefit in patients with lower angiotensin II levels. The ≤ 5 ng kg−1 min−1 subgroup had a more favorable safety profile and lower treatment discontinuation rate than the > 5 ng kg−1 min−1 subgroup. Conclusions: This prespecified analysis showed that down-titration to ≤ 5 ng kg−1 min−1 angiotensin II at 30 min is an early predictor of favorable clinical outcomes which may be related to relative angiotensin II insufficiency.",
keywords = "Angiotensin II, Dose response, Hypotension, Septic shock, Shock",
author = "Ham, {Kealy R.} and Boldt, {David W.} and McCurdy, {Michael T.} and Busse, {Laurence W.} and Raphael Favory and Gong, {Michelle Ng} and Khanna, {Ashish K.} and Chock, {Stefan N.} and Feng Zeng and Chawla, {Lakhmir S.} and Tidmarsh, {George F.} and Marlies Ostermann",
year = "2019",
month = "12",
day = "1",
doi = "10.1186/s13613-019-0536-5",
language = "English (US)",
volume = "9",
journal = "Annals of Intensive Care",
issn = "2110-5820",
publisher = "Springer-Verlag GmbH and Co. KG",
number = "1",

}

TY - JOUR

T1 - Sensitivity to angiotensin II dose in patients with vasodilatory shock

T2 - a prespecified analysis of the ATHOS-3 trial

AU - Ham, Kealy R.

AU - Boldt, David W.

AU - McCurdy, Michael T.

AU - Busse, Laurence W.

AU - Favory, Raphael

AU - Gong, Michelle Ng

AU - Khanna, Ashish K.

AU - Chock, Stefan N.

AU - Zeng, Feng

AU - Chawla, Lakhmir S.

AU - Tidmarsh, George F.

AU - Ostermann, Marlies

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg−1 min−1 angiotensin II at 30 min (≤ 5 ng kg−1 min−1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus patients receiving > 5 ng kg−1 min−1 angiotensin II at 30 min (> 5 ng kg−1 min−1 subgroup). Data from angiotensin II-treated patients enrolled in the ATHOS-3 trial were used. Results: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg−1 min−1 at treatment initiation to ≤ 5 ng kg−1 min−1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg−1 min−1 subgroup (84/163). Patients in the ≤ 5 ng kg−1 min−1 subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg−1 min−1 subgroup (90% vs. 51%, respectively; odds ratio, 8.46 [95% CI 3.63–19.7], P < 0.001). Day 28 survival was also higher in the ≤ 5 ng kg−1 min−1 subgroup versus the > 5 ng kg−1 min−1 subgroup (59% vs. 33%, respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], P = 0.0007); multivariate analyses supported the survival benefit in patients with lower angiotensin II levels. The ≤ 5 ng kg−1 min−1 subgroup had a more favorable safety profile and lower treatment discontinuation rate than the > 5 ng kg−1 min−1 subgroup. Conclusions: This prespecified analysis showed that down-titration to ≤ 5 ng kg−1 min−1 angiotensin II at 30 min is an early predictor of favorable clinical outcomes which may be related to relative angiotensin II insufficiency.

AB - Background: Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg−1 min−1 angiotensin II at 30 min (≤ 5 ng kg−1 min−1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus patients receiving > 5 ng kg−1 min−1 angiotensin II at 30 min (> 5 ng kg−1 min−1 subgroup). Data from angiotensin II-treated patients enrolled in the ATHOS-3 trial were used. Results: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg−1 min−1 at treatment initiation to ≤ 5 ng kg−1 min−1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg−1 min−1 subgroup (84/163). Patients in the ≤ 5 ng kg−1 min−1 subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg−1 min−1 subgroup (90% vs. 51%, respectively; odds ratio, 8.46 [95% CI 3.63–19.7], P < 0.001). Day 28 survival was also higher in the ≤ 5 ng kg−1 min−1 subgroup versus the > 5 ng kg−1 min−1 subgroup (59% vs. 33%, respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], P = 0.0007); multivariate analyses supported the survival benefit in patients with lower angiotensin II levels. The ≤ 5 ng kg−1 min−1 subgroup had a more favorable safety profile and lower treatment discontinuation rate than the > 5 ng kg−1 min−1 subgroup. Conclusions: This prespecified analysis showed that down-titration to ≤ 5 ng kg−1 min−1 angiotensin II at 30 min is an early predictor of favorable clinical outcomes which may be related to relative angiotensin II insufficiency.

KW - Angiotensin II

KW - Dose response

KW - Hypotension

KW - Septic shock

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=85066600759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066600759&partnerID=8YFLogxK

U2 - 10.1186/s13613-019-0536-5

DO - 10.1186/s13613-019-0536-5

M3 - Article

AN - SCOPUS:85066600759

VL - 9

JO - Annals of Intensive Care

JF - Annals of Intensive Care

SN - 2110-5820

IS - 1

M1 - 63

ER -